HOWL logo

WEREWOLF THERAPEUTICS INC

HOWLNASDAQ
🏆 #4501 by market capUS Equity
$976.24▲ $25.09 (+2.57%)
Simulated price
🔔
Track HOWL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$45M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
86.4%
High
💵FCF Margin
-143.6%
Thin
⚖️P/S Ratio
2.2x
Cheap
Otter Score
88
Very Good
No chart data available for HOWL.

Trading Snapshot

Day Range
$961.26 – $981.40
52-Week Range
$0.27 – $2.38
Volume
$3.17B
Avg Volume
$2.24B
Shares Outstanding
48.6M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$21M
Last Q Revenue
$21M
P/E Ratio
-1.3
P/S Ratio
2.2x
EPS (TTM)
$-0.71
Dividend Yield
0.00%
Dilution (1yr)
+5.2%

Why Investors Own HOWL

  • ✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HOWL logo

WEREWOLF THERAPEUTICS INC

HOWL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.8%▼ −95.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$61M▼ −17.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$60M▲ +6.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8M▲ +5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19M▼ −$55M YoY
StockOtter · stockotter.space

About WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$1,112.29
▲ +13.9% Upside
High Target$1,317.99
Low Target$1,028.19
Based on 22 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

WEREWOLF THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift HOWL price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

WEREWOLF THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.